Non-Invasive Evaluation of Liver Steatosis, Inflammation and Fibrosis

The study group proposes to evaluate the role of KBD FDG-PET in the determination of
steatohepatitis and in combination with MRI for detection, differentiation and quantitation
of liver steatosis, steatohepatitis and fibrosis in correlation to liver biopsy. Patient
enrolled in this will already have had their liver biopsy or will be undergoing liver biopsy
as a part of their clinical care as determined by their provider and will not be getting
biopsies solely to be enrolled in the study. Current treatment options for patients that
liver biopsy is being performed are limited to lifestyle changes and vitamin E for patients
without diabetes.

Inclusion Criteria:

1. Patients >18 years age

2. Patients who had or will have a liver biopsy as standard of care for fatty liver
disease and have risk factors for NASH. Liver biopsy needs to be within 6 months of
planned imaging.

3. Patients undergoing bariatric surgery and will have a liver biopsy as standard of
care.

4. Ability to provide informed consent.

Exclusion Criteria:

1. History of alcohol abuse, chronic hepatitis B or C, or other chronic liver disease
other than non-alcoholic fatty liver disease.

2. Pregnant women

3. Prisoners

4. Claustrophobic to MRI

5. Allergic to FDG dye

6. Patients who are unable to lie in the scanner for one hour